Please login to the form below

Not currently logged in
Email:
Password:

rociletinib

This page shows the latest rociletinib news and features for those working in and with pharma, biotech and healthcare.

FDA okays Clovis' Lynparza rival rucaparib

FDA okays Clovis' Lynparza rival rucaparib

The company has been pummelled in recent months after an FDA advisory panel voted against a quick approval of its lung cancer candidate rociletinib, a decision that eventually prompted the company

Latest news

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    FDA panel says no to quick approval of Clovis' rociletinib. Recommends waiting for phase III trial results after "serious" safety concerns. ... An FDA advisory committee all but dashed any hopes that Clovis Oncology had for quick approval of its lung

  • AZ sets price of new lung cancer drug Tagrisso AZ sets price of new lung cancer drug Tagrisso

    The FDA has asked for more data on the drug - called rociletinib - which could potentially hold up the programme by several months. ... The FDA's problems with the dataset for rociletinib hinge on the number of unconfirmed versus confirmed responses to

  • Boehringer takes third-generation NSCLC drug into pivotal trials Boehringer takes third-generation NSCLC drug into pivotal trials

    chemotherapy. Aside from Boehringer, other companies developing third-generation EGFR inhibitors include Clovis Oncology with twice-daily rociletinib (CO-1686) and AZ with once-daily osimertinib/AZD9291, both of which are ... Clinical data on both

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics